Northern Trust
STOK icon

Northern Trust’s Stoke Therapeutics STOK Stock Holding History

Northern Trust’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.4M Buy
500,124
+68,494
+16% +$2.2M ﹤0.01% 1912
2026
Q1 		$14.1M Buy
431,630
+28,462
+7% +$933K ﹤0.01% 1888
2025
Q4 		$12.8M Sell
403,168
-11,749
-3% -$353K ﹤0.01% 1949
2025
Q3 		$9.75M Sell
414,917
-8,637
-2% -$148K ﹤0.01% 2120
2025
Q2 		$4.81M Buy
423,554
+76,890
+22% +$730K ﹤0.01% 2476
2025
Q1 		$2.31M Sell
346,664
-4,124
-1% -$38.5K ﹤0.01% 2844
2024
Q4 		$3.87M Buy
350,788
+11,635
+3% +$143K ﹤0.01% 2656
2024
Q3 		$4.17M Buy
339,153
+56,538
+20% +$801K ﹤0.01% 2587
2024
Q2 		$3.82M Buy
282,615
+21,724
+8% +$293K ﹤0.01% 2540
2024
Q1 		$3.52M Buy
260,891
+3,299
+1% +$20K ﹤0.01% 2681
2023
Q4 		$1.35M Sell
257,592
-7,781
-3% -$33.3K ﹤0.01% 3189
2023
Q3 		$1.05M Sell
265,373
-2,762
-1% -$18.2K ﹤0.01% 3280
2023
Q2 		$2.85M Buy
268,135
+71,354
+36% +$759K ﹤0.01% 2808
2023
Q1 		$1.64M Sell
196,781
-1,735
-0.9% -$15.7K ﹤0.01% 3023
2022
Q4 		$1.83M Sell
198,516
-5,199
-3% -$54.1K ﹤0.01% 3048
2022
Q3 		$2.62M Sell
203,715
-2,086
-1% -$33.2K ﹤0.01% 2869
2022
Q2 		$2.72M Buy
205,801
+19,166
+10% +$291K ﹤0.01% 2882
2022
Q1 		$3.93M Buy
186,635
+251
+0.1% +$5.03K ﹤0.01% 2729
2021
Q4 		$4.47M Sell
186,384
-558
-0.3% -$13.3K ﹤0.01% 2754
2021
Q3 		$4.76M Sell
186,942
-10,310
-5% -$287K ﹤0.01% 2766
2021
Q2 		$6.64M Buy
197,252
+10,592
+6% +$374K ﹤0.01% 2655
2021
Q1 		$7.25M Sell
186,660
-13,310
-7% -$758K ﹤0.01% 2509
2020
Q4 		$12.4M Buy
199,970
+5,413
+3% +$248K ﹤0.01% 2111
2020
Q3 		$6.52M Buy
194,557
+4,597
+2% +$131K ﹤0.01% 2375
2020
Q2 		$4.53M Sell
189,960
-11,177
-6% -$265K ﹤0.01% 2582
2020
Q1 		$4.61M Buy
201,137
+83,733
+71% +$2.07M ﹤0.01% 2351
2019
Q4 		$3.33M Buy
117,404
+9,508
+9% +$239K ﹤0.01% 2826
2019
Q3 		$2.32M Buy
+107,896
New +$3.01M ﹤0.01% 3020

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust's STOK Position: Q2 2026 in Review

Northern Trust increased its Stoke Therapeutics (STOK) stake by 16% in Q2 2026, buying an estimated $2.2M and bringing the position to 500,124 shares worth $16.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1912.

Northern Trust first reported a position in STOK in Q3 2019 and has held it in 28 quarters since. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Northern Trust held 500,124 shares of Stoke Therapeutics worth $16.4M as of Q2 2026.
  • Northern Trust bought 68,494 Stoke Therapeutics shares in Q2 2026, an estimated $2.2M.
  • Stoke Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #1912 holding.
  • Northern Trust first reported a position in Stoke Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.